Summary:
Phase 3 double blind trial in patients with moderate to severe Ulcerative Colitis
Qualified Participants Must:
• Be 16 to 80 years of age
•
Have inadequate response to 1 conventional traetment (eg,Methotrexate, immunosuppressants, mesalamine, anti-TNF
•
Must have documentation of UC diagnosis for more than 3months
Qualified Participants May Receive:
- Participants will receive study medication at no cost to them
- Patients may be reimbursed for any travel expenses incurred as a result of taking part in the study